Author name: Leonardo Arias

A depleter of pathogenic T cells, rosnilimab’s novel MOA generated a differentiated efficacy, tolerability and safety profile in recent Phase 2b study

On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer drug Keytruda.

While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting this week, experts told BioSpace the conference will also provide important insights into the therapeutic benefits of incretin therapies beyond weight loss.

After decades without much movement, a handful of new treatments for this rare autoimmune disease are now approved, and several companies, including argenx and Regeneron, have recently released promising late-stage trial results.

Medical device companies working with artificial intelligence raised funding and were acquisition targets in recent months.

Jon Thiboutot, most recently the vice president of operations of CVS’ MinuteClinic subsidiary, has been named the healthcare giant’s president of retail health.

Chair Andrew Ferguson has sent letters to large healthcare employers and staffing firms asking them to review their employment contracts as the FTC pursues targeted enforcement of illegal noncompetes.

En los últimos años, los avances médicos han permitido mejorar el diagnóstico y seguimiento de enfermedades crónicas y degenerativas que antes pasaban desapercibidas. Sin embargo, la ciencia no siempre camina al mismo ritmo que la realidad social y laboral de quien …

The bipartisan legislation, introduced this week in the House and Senate, seeks to prevent more cuts to Medicare reimbursement rates for diagnostic tests.

President Donald Trump is considering tariff exemptions for certain “non-patented” pharmaceuticals, though the White House has yet to release specific guidelines.